Standard celiac blood tests can return to normal while the gut is still damaged. A new study finds that a different blood marker — one that directly reflects intestinal cell health — detects that hidden damage when conventional tests miss it entirely.
Researchers at Marche Polytechnic University in Ancona, Italy, publishing in Clinical and Translational Gastroenterology, measured levels of a protein called IFABP in celiac patients and found it tracks actual gut healing far more closely than standard antibody tests. Critically, IFABP remained elevated in patients who had been following a long-term gluten-free diet, reported good dietary adherence, and had normal celiac serology — signaling that their guts were not as healed as routine testing suggested.
For celiac families, this is a meaningful finding. It points toward a blood test that could give doctors a real-time view of intestinal healing without requiring another endoscopy and biopsy.
What This Means for You
If someone in your family has celiac disease, follow-up antibody blood tests are a familiar part of monitoring. The most common of these is the anti-tTG IgA test. When it normalizes, that’s typically treated as a sign of recovery.
As the parent of a celiac kid, I know how much weight those numbers carry. When the results come back normal, it feels like a win. What this research suggests is that “normal” may not mean fully healed.
Studies have shown that a portion of celiac patients on a strict gluten-free diet still have measurable intestinal damage on biopsy — even after years on the diet, even when their antibody tests look fine. As we explored in our analysis of anti-tTG IgA predictive accuracy, serology has real limits when it comes to reflecting what’s actually happening in the small intestine.
IFABP works by a different mechanism. It’s a protein released by intestinal cells when those cells are damaged. When the gut lining is under attack — as it is in active celiac disease — IFABP leaks into the bloodstream. As the gut heals, levels fall. This makes it a direct signal of current intestinal cell health, not just an indirect immune marker like an antibody test.
In this study, higher IFABP levels predicted ongoing subtle gut abnormalities in patients on a long-term gluten-free diet, even when their standard antibody tests were normal and they reported following the diet carefully. That gap matters. It suggests celiac patients could carry ongoing gut damage that neither their blood tests nor their self-reported diet adherence would flag.
Key Takeaways
- Standard celiac antibody tests can normalize even when significant gut damage remains.
- IFABP is a blood protein released when intestinal cells are damaged — and its levels closely track actual mucosal healing.
- In celiac patients following a long-term gluten-free diet, higher IFABP predicted ongoing subtle gut abnormalities even when antibody tests were normal.
- IFABP could become a non-invasive way to monitor healing without repeat biopsies.
- This research was conducted in adults; it’s not yet a clinical monitoring tool, but the results are strong enough to watch closely.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What IFABP Is and Why It Matters
IFABP stands for intestinal fatty acid binding protein. It’s a small protein found inside enterocytes — the specialized cells that line the small intestine and absorb nutrients. Under normal conditions, IFABP stays inside those cells. When enterocytes are damaged or die, IFABP leaks out and enters the bloodstream.
This makes it a damage-specific biomarker: its presence in the blood is a direct signal that intestinal cells are under attack. The greater the damage, the higher the serum (blood) IFABP level.
In celiac disease, gluten triggers an immune response that destroys the finger-like projections called villi (singular: villus) that line the small intestine and absorb nutrients. That destruction raises IFABP levels. When the gluten-free diet allows the gut to recover, IFABP should fall. The question this study set out to answer: how precisely does it track that recovery, and can it detect partial or subtle damage?
How the Study Was Designed
The team enrolled two groups of adult celiac patients:
- Newly diagnosed (ND): patients with confirmed celiac disease who had not yet started a gluten-free diet
- Follow-up (FU): patients who had been on a gluten-free diet for at least 18 months
Both groups provided blood draws for IFABP measurement and underwent duodenal biopsies — tissue samples from the first section of the small intestine. Those samples underwent quantitative morphometric analysis, meaning researchers measured specific structural features of the intestinal lining with numerical precision rather than simply grading damage by eye.
The morphometric measurements included:
- Villous height to crypt depth ratio (Vh:Cd): A structural measure of mucosal architecture. Healthy intestines have tall, well-formed villi. In celiac disease, villi flatten and the crypts (recesses between villi) deepen. A lower Vh:Cd ratio indicates more damage.
- Intraepithelial lymphocyte (IEL) count: IELs are immune cells embedded within the intestinal lining itself. In celiac disease, IEL counts rise as the immune system attacks gut tissue. Elevated IELs signal active immune injury even when structural damage looks mild.
- VCIEL index: A composite score combining both the Vh:Cd ratio and the IEL count into a single mucosal health number, designed to capture the full picture of damage more completely than either measure alone.
IFABP levels were measured using ELISA (enzyme-linked immunosorbent assay), a standard laboratory technique for detecting and quantifying specific proteins in blood.
What the Numbers Showed
The results were clear and statistically strong across the board.
Newly diagnosed patients had significantly higher IFABP levels than follow-up patients (p < 0.001) — confirming the basic hypothesis that active, untreated celiac disease raises IFABP.
The correlations with biopsy data are where the study becomes clinically significant:
- IFABP correlated negatively with Vh:Cd ratio (ρ = −0.53, p < 0.001): as gut architecture worsened, IFABP rose.
- IFABP correlated positively with IEL count (ρ = 0.46, p < 0.001): as immune cell infiltration increased, so did IFABP.
- IFABP showed its strongest correlation with the composite VCIEL index (ρ = −0.60, p < 0.001): the more damaged the gut overall, the higher the blood protein level.
A correlation of ρ = −0.60 is moderately strong in biological research — notably better than what conventional celiac antibody tests typically achieve when compared directly to biopsy findings.
The most clinically important result came from the follow-up group. Among patients on a long-term gluten-free diet, IFABP still predicted subtle morphometric abnormalities — reduced Vh:Cd and elevated IELs — but it did not correlate with standard celiac serology results or self-reported dietary adherence. IFABP captured ongoing damage that the usual tests and patient reports missed entirely.
Where This Fits in the Broader Search for Non-Invasive Monitoring
The gold standard for monitoring mucosal healing in celiac disease remains the duodenal biopsy. But biopsies require endoscopy — they’re invasive, costly, and a real barrier to repeat monitoring, especially for children. The search for reliable blood or urine markers that could replace or reduce the need for biopsies has become one of the more active areas of celiac research.
This study joins a growing body of work in that direction. We’ve previously covered research into urinary microRNAs as non-invasive diagnostic markers in pediatric patients — a different biological signal, but the same goal: find something measurable outside the gut that accurately reflects what’s happening inside it.
IFABP has appeared in earlier celiac studies, but this paper adds an important methodological step: direct comparison to quantitative morphometric biopsy data, rather than standard Marsh histological grading alone. That precision makes the correlations more meaningful and the conclusions more reliable.
One significant limitation: this is a cross-sectional study, capturing measurements at a single point in time rather than following patients over months or years. That means we don’t yet know how quickly IFABP responds to dietary changes, or whether it could detect accidental gluten exposure before symptoms appear. Future longitudinal studies will need to address that. The adult-only enrollment also leaves open the question of how well these findings apply to celiac children.
Still, the core conclusion holds: a simple blood draw reflects the actual state of the gut more accurately than either patient-reported adherence or conventional antibody panels. For a community that has long lacked good tools for monitoring real mucosal recovery, that’s a meaningful step forward.
Related Coverage
- Predictive capacity of anti-tissue-transglutaminase IgA antibodies to identify intestinal villous atrophy in celiac disease
- Urinary miR-221-3p and miR-324-5p in combination with albuminuria as a promising model for non-invasive diagnosis of pediatric celiac disease
References
Monachesi C, Ascani M, Di Sario F, et al. Serum IFABP level as an index of mucosal health in celiac disease: a small intestinal morphometry study. Clin Transl Gastroenterol. 2026 Jul 1. doi: 10.14309/ctg.0000000000001067